Medlab Clinical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Sean Hall

Algemeen directeur

AU$574.1k

Totale compensatie

Percentage CEO-salaris	76.9%
Dienstverband CEO	9.1yrs
Eigendom CEO	17.2%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Sean Hall's beloning veranderd ten opzichte van Medlab Clinical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2022	AU$574k	AU$441k	-AU$8m
Mar 31 2022	n/a	n/a	-AU$9m
Dec 31 2021	n/a	n/a	-AU$12m
Sep 30 2021	n/a	n/a	-AU$12m
Jun 30 2021	AU$677k	AU$372k	-AU$10m
Mar 31 2021	n/a	n/a	-AU$10m
Dec 31 2020	n/a	n/a	-AU$11m
Sep 30 2020	n/a	n/a	-AU$12m
Jun 30 2020	AU$379k	AU$300k	-AU$13m
Mar 31 2020	n/a	n/a	-AU$12m
Dec 31 2019	n/a	n/a	-AU$12m
Sep 30 2019	n/a	n/a	-AU$10m
Jun 30 2019	AU$364k	AU$299k	-AU$8m
Mar 31 2019	n/a	n/a	-AU$7m
Dec 31 2018	n/a	n/a	-AU$6m
Sep 30 2018	n/a	n/a	-AU$5m
Jun 30 2018	AU$328k	AU$299k	-AU$5m
Mar 31 2018	n/a	n/a	-AU$4m
Dec 31 2017	n/a	n/a	-AU$4m
Sep 30 2017	n/a	n/a	-AU$4m
Jun 30 2017	AU$328k	AU$299k	-AU$4m
Mar 31 2017	n/a	n/a	-AU$4m
Dec 31 2016	n/a	n/a	-AU$4m
Sep 30 2016	n/a	n/a	-AU$4m
Jun 30 2016	AU$328k	AU$299k	-AU$3m

Compensatie versus markt: De totale vergoeding ($USD 381.75K ) Sean } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 297.98K ).

Compensatie versus inkomsten: De vergoeding van Sean is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sean Hall (52 yo)

9.1yrs

Tenure

AU$574,110

Compensatie

Dr. Sean Michael Hall serves as the Chief Executive Officer at Medlab Clinical Limited and served as its Managing Director. He served as a Managing Director of Medlab Clinical Limited until November 2020....

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sean Hall	MD, CEO & Director	9.1yrs	AU$574.11k	17.18% A$ 2.6m
Michael Carter	Director	less than a year	geen gegevens	geen gegevens
Matthew Hudson	Director	less than a year	geen gegevens	geen gegevens

0.2yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van MDC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.2 jaar), wat duidt op een nieuw bestuur.

Medlab Clinical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Less than half of directors are independent

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

Recent updates

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

New 90-day high: AU$0.28

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.23

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur